Type 2 Diabetes Mellitus and Chronic Kidney Disease
- Conditions
- Renal Disorder Associated With Type II Diabetes Mellitus
- Interventions
- Diagnostic Test: Hematologic tests for patients with diabetes mellitus and chronic kidney disease
- Registration Number
- NCT04971252
- Lead Sponsor
- Sohag University
- Brief Summary
To investigate the effect of co existance of diabetes mellitus and chronic kidney disease on basic coagulation profile in comparison with diabetic patients with normal kidney function and non diabetic patients with chronic kidney disease
- Detailed Description
We will study impact of type 2 diabetes mellitus on basic coagulation profile and platelet indices among patients with chronic kidney disease
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 150
- Patients with diabetes mellitus with and without chronic kidney disease Patients with chronic kidney disease without diabetes mellitus
- any situation influence on basic coagulation profile and platelet indices other than diabetes mellitus and chronic kidney disease
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Co existance of diabetes mellitus and chronic kidney disease Hematologic tests for patients with diabetes mellitus and chronic kidney disease Study basic coagulation profile and platelet indices among those patients with combined diabetes mellitus and chronic kidney disease Diabetes mellitus without chronic kidney disease Hematologic tests for patients with diabetes mellitus and chronic kidney disease Study basic coagulation profile and platelet indices among those patients with diabetes mellitus only Chronic kidney disease without diabetes mellitus Hematologic tests for patients with diabetes mellitus and chronic kidney disease Study basic coagulation profile and platelet indices among those patients with chronic kidney disease without diabetes mellitus
- Primary Outcome Measures
Name Time Method Estimate risk of thrombosis or bleeding for the 3 study groups by partial thromboplastin time 1 day We will include 150 patients as previous Fourth measure is partial thromboplastin time
Estimate risk of thrombosis or bleeding for the 3 study groups by serum fibrinogen 1 day We will include 150 patients as previous Fifth measure is serum fibrinogen level in the 3 groups
Estimate risk of thrombosis or bleeding for the 3 study groups by platelet distribution width 1 day We will include 150 patients as previous Seventh measure is platelet distribution width for the 3 groups
Estimate risk of thrombosis or bleeding for the 3 study groups by prothrombin time 1 day We will include 150 patients and classify them into 3 groups each one consists of 50 patients First group those patients with diabetes mellitus only Second group those patients with chronic kidney disease only Third group those patients with combined diabetes mellitus type 2 and chronic kidney disease not on hemodialysis First we will measure prothrombin time
Estimate risk of thrombosis or bleeding for the 3 study groups by plateletcrit 1 day We will include 150 patients as previous Eighth measure is plateletcrit of the 3 study groups
Estimate risk of thrombosis or bleeding for the 3 study groups by prothrombin concentration 1 day We will include 150 patients classified into 3 groups as previous Second measure is prothrombin concentration
Estimate risk of thrombosis or bleeding for the 3 study groups by INR 1 day We will include 150 patients as previous Third measure is INR ( international normalised ratio )
Estimate risk of thrombosis or bleeding for the 3 study groups by mean platelet volume 1 day We will include 150 patients as previous Sixth measure is mean platelet volume in the 3 groups
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Sohag University
🇪🇬Sohag, Egypt